Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia
- PMID: 11502458
- DOI: 10.1016/s0090-4295(01)01248-1
Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia
Abstract
There is a marked decrease in the prevalence and extent of high-grade prostatic intraepithelial neoplasia (PIN) in men with prostate cancer after androgen deprivation therapy (ADT) when compared with untreated cases. Basal cell hyperplasia, cytoplasmic clearing, and prominent atrophy of benign acini, with decreased ratio of acini to stroma, accompany this decrease. These findings indicate that the benign and dysplastic prostatic epithelium is androgen dependent. In the normal prostatic epithelium, luminal secretory cells are more sensitive to the absence of androgen than basal cells, and the proliferative cells of high-grade PIN share this androgen sensitivity. The loss of some normal, hyperplastic, and dysplastic epithelial cells with ADT is probably because of acceleration of programmed single-cell death. Remarkably little is known about the comparative effect of different forms of chemical ADT on PIN and cancer, although there appears to be a limited and consistent repertoire of morphologic responses to all forms of this therapy. Conversely, blockade of 5alpha-reductase with finasteride has little or no effect on PIN (or benign epithelium and cancer), unlike other forms of ADT. A recent international consensus conference sponsored by the World Health Organization concluded that identification of high-grade PIN offered the possibility of chemoprevention with hormonal therapy to block the development of clinical cancer. Multiple chemoprevention trials are planned or under way to address this hypothesis.
Similar articles
-
Androgen deprivation therapy for precancerous lesions of the prostate.Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):285-91. doi: 10.1016/j.beem.2008.01.006. Best Pract Res Clin Endocrinol Metab. 2008. PMID: 18471786 Review.
-
Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development.Urology. 2001 Aug;58(2 Suppl 1):83-90. doi: 10.1016/s0090-4295(01)01247-x. Urology. 2001. PMID: 11502457 Review.
-
Prostatic intraepithelial neoplasia and prostate cancer.Panminerva Med. 2002 Sep;44(3):213-20. Panminerva Med. 2002. PMID: 12094135 Review.
-
Influence of irradiation and androgen ablation on prostatic intraepithelial neoplasia.Eur Urol. 1996;30(2):261-4. doi: 10.1159/000474178. Eur Urol. 1996. PMID: 8875209 Review.
-
Functional heterogeneity of prostatic intraepithelial neoplasia: the duration of hormonal therapy influences the response.BJU Int. 2007 May;99(5):1024-7. doi: 10.1111/j.1464-410X.2006.06738.x. Epub 2007 Jan 22. BJU Int. 2007. PMID: 17244277
Cited by
-
Anti-proliferation Effect of Polypeptide Extracted from Scorpion Venom on Human Prostate Cancer Cells in vitro.J Clin Med Res. 2009 Apr;1(1):24-31. doi: 10.4021/jocmr2009.01.1220. Epub 2009 Mar 24. J Clin Med Res. 2009. PMID: 22505961 Free PMC article.
-
Drug therapies for eradicating high-grade prostatic intraepithelial neoplasia in the prevention of prostate cancer.Rev Urol. 2005;7 Suppl 3(Suppl 3):S19-29. Rev Urol. 2005. PMID: 16985876 Free PMC article.
-
A novel murine model of allogeneic vaccination against prostate cancer.Cancer Immunol Immunother. 2008 Apr;57(4):453-65. doi: 10.1007/s00262-007-0384-2. Epub 2007 Sep 6. Cancer Immunol Immunother. 2008. PMID: 17805533 Free PMC article.
-
High-grade prostatic intraepithelial neoplasia of the prostate: the precursor lesion of prostate cancer.Int J Clin Exp Pathol. 2009;2(4):327-38. Epub 2008 Dec 22. Int J Clin Exp Pathol. 2009. PMID: 19158990 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources